Citations

Clear

7552 citation(s) found for "Ho, Matthew".

[IC‐P‐021]: INVESTIGATION OF PITTSBURGH COMPOUND‐B BINDING IN WHITE MATTER HYPERINTENSITIES
Lowe, Val J. , Przybelski, Scott A. , Lesnick, Timothy G. , Kantarci, Orhun H. , Petersen, Ronald C. , Zeydan, Burcu , Schwarz, Christopher G. , Kremers, Walter K. , Senjem, Matthew L. , Knopman, David S. , Jack, Clifford R. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2017.06.2293 Get It

[P4–531]: TDP‐43 DRIVES FASTER RATES OF HIPPOCAMPAL ATROPHY IN ALZHEIMER's DISEASE STARTING AT LEAST 10 YEARS PRIOR TO DEATH
Josephs, Keith A. , Tosakulwong, Nirubol , Weigand, Stephen D. , Petrucelli, Leonard , Liesinger, Amanda M., Spychalla, Anthony J., Parisi, Joseph E., Petersen, Ronald C. , Whitwell, Jennifer L. , Dickson, Dennis W. , Murray, Melissa E. , Senjem, Matthew L. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_32 | Pages: No page available

10.1016/j.jalz.2017.07.693 Get It

[P3–343]: INVESTIGATION OF PITTSBURGH COMPOUND‐B BINDING IN WHITE MATTER HYPERINTENSITIES
Lowe, Val J. , Przybelski, Scott A. , Lesnick, Timothy G. , Kantarci, Orhun H. , Petersen, Ronald C. , Zeydan, Burcu , Schwarz, Christopher G. , Kremers, Walter K. , Senjem, Matthew L. , Knopman, David S. , Jack, Clifford R. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_22 | Pages: No page available

10.1016/j.jalz.2017.06.1558 Get It

Dose-Response Association of CD8 + Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Goode, Ellen L. , Block, Matthew S. , Kalli, Kimberly R., Vierkant, Robert A. , Fogarty, Zachary C. , Tołoczko, Aleksandra, Hein, Alexander , Bouligny, Aliecia L., Jensen, Allan , Osório, Ana , Ryan, Andy , Magliocco, Anthony M., Hartmann, Arndt , Gao, Bo , McCauley, Bryan M. , Kennedy, Catherine J. , Karpinskyj, Chloe , Sousa, Christiani Bisinoto de, Tiezzi, Daniel Guimarães , Wachter, David L., Herpel, Esther , Taran, Florin‐Andrei , Nelson, Gregg , Menkiszak, Janusz , Alsop, Jennifer , Lester, Jenny , García-Donás, Jesús , Nation, Jill, Hung, Jillian A., Palacios, José , Rothstein, Joseph H. , Kelley, Joseph L., Andrade, Jurandyr Moreira de , Robles-Díaz, Luis, Intermaggio, Maria P., Widschwendter, Martin , Beckmann, Matthias W. , Ruebner, Matthias , Jimenez‐Liñan, Mercedes , Singh, Naveena , Oszurek, Oleg, Harnett, Paul R. , Rambau, Peter , Sinn, Hans‐Peter , Wagner, Philipp , Sharma, Raghwa , Ness, Roberta B., Oršulić, Sandra , Johnatty, Sharon E., Longacre, Teri A. , Eilber, Ursula, McGuire, Valerie , Sieh, Weiva , Natanzon, Yanina , Li, Zheng , Whittemore, Alice S. , DeFazio, Anna , Staebler, Annette , Bowtell, David D.L. , Høgdall, Estrid , Reis, Francisco José Cândido dos , Steed, Helen , Campbell, Ian , Benı́tez, Javier , Koziak, Jennifer M. , Chang‐Claude, Jenny, Moysich, Kirsten B. , Kelemen, Linda E. , Goodman, Marc T. , García, María J. , Fasching, Peter A. , Kommoss, Stefan , Deen, Suha , Menon, Usha , Chenevix‐Trench, Georgia , Huntsman, David G. , Köbel, Martin , Ramus, Susan J. , Winham, Stacey J. , Fazio, Anna de , Ramus, Susan J , Köbel, Martin , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Campbell, Ian G , García-Donas, Jesús , Kennedy, Catherine J , Menkiszak, Janusz , Sinn, Peter , Widschwendter, Martin , Fogarty, Zachary C , Sieh, Weiva , Benitez, Javier , Chenevix-Trench, Georgia , Høgdall, Estrid , Bowtell, David D , Chen, Wenqian , Gentry‐Maharaj, Aleksandra , Bouligny, Aliecia, Hartkopf, Andreas D , Chudecka-Glaz, Anita Monika , Jung, Audrey , Hernandez, Brenda Y. , Fridley, Brooke L. , Wang, Chen , Modugno, Francesmary , Lubiński, Jan , Robles-Díaz, Luis, Ghatage, Prafull , Edwards, Todd , Brucker, Sara Yvonne , Karlan, Beth Y. , Gilks, C. Blake , Gronwald, Jacek , Cook, Linda S. , Kjær, Susanne K. , Brenton, James D. , Pharoah, Paul D.P. , Nelson, Gregg S , Harnett, Paul R , Steed, Helen , Goodman, Marc T

Mayo Clinic

JAMA Oncology | October 19, 2017 | Volume: 3 | Issue: 12 | Pages: e173290

10.1001/jamaoncol.2017.3290 | PMID 29049607 Get It

Editorial Comment on: The Decline of Laparoendoscopic Single-Site Surgery: A Survey of the Endourological Society to Identify Shortcomings and Guidance for Future Directions by Sorokin et al .(From: Sorokin I,
Gettman, Matthew T.

Mayo Clinic

Journal of Endourology | October 19, 2017 | Volume: 31 | Issue: 12 | Pages: 1343-1344

10.1089/end.2017.0688 | PMID 29048229 Get It

Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes
Fanaroff, Alexander C. , Manandhar, Pratik , Holmes, David R. , Harrison, J. Kevin , Thourani, Vinod H. , Mack, Michael J. , Sherwood, Matthew W. , Vemulapalli, Sreekanth , Douglas, Pamela S. , Hughes, G Chad, Jones, W Schuyler, Douglas, Pamela S , Cohen, David Jonathan , Hughes, George Chad , Jones, W. Schuyler , Fanaroff, Alexander C

Mayo Clinic

Circulation: Cardiovascular Interventions | October 17, 2017 | Volume: 10 | Issue: 10 | Pages: No page available

10.1161/circinterventions.117.005456 | PMID 29042398 Get It

Background— Peripheral artery disease (PAD) is associated with increased cardiovascular mortality, and PAD risk factors overlap with those for aortic stenosis. The prevalence and outcomes associated with PAD in a population undergoing transcatheter aortic valve replacement (TAVR) are unknown. Methods and Results— Using the Society of Thoracic Surgeons/Transcatheter Valve Therapy Registry linked to Medicare claims data, we identified patients ≥65 years old undergoing TAVR from 2011 to 2015. We calculated hazard ratios for 1-year adverse outcomes, including mortality, readmission, and bleeding, for patients with PAD compared with those without, adjusting for baseline characteristics and postprocedure medications. Analyses were performed separately by access site (transfemoral and nontransfemoral). Of 19 660 patients undergoing transfemoral TAVR, 4810 (24.5%) had PAD; 3730 (47.9%) of 7780 patients undergoing nontransfemoral TAVR had PAD. In both groups, patients with PAD were significantly more likely to have coronary and carotid artery diseases. At 1-year follow-up, patients with PAD undergoing TAVR via transfemoral access had a higher incidence of death (16.8% versus 14.4%; adjusted hazard ratio, 1.14; P =0.01), readmission (45.5% versus 42.1%; hazard ratio, 1.11; P <0.001), and bleeding (23.1% versus 19.7%; hazard ratio, 1.18; P <0.001) compared with patients without PAD. Patients with PAD undergoing TAVR via nontransfemoral access did not have significantly higher rates of 1-year mortality or readmission compared with patients without PAD. Conclusions— PAD is common among patients undergoing commercial TAVR via transfemoral and nontransfemoral access. Among patients undergoing transfemoral TAVR, PAD is associated with a higher incidence of 1-year adverse outcomes compared with absence of PAD. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01737528.
Relationship of Aortic Wall Distensibility to Mitral and Aortic Valve Calcification: The Multi-Ethnic Study of Atherosclerosis
Cohoon, Kevin P. , Criqui, Michael H. , Budoff, Matthew J. , Decker, Paul A. , Durazo, Ramón, Liu, Kiang , Budoff, Matthew , Lima, João A.C. , Blaha, Michael Joseph , Decker, Paul A. , Kramer, Holly

Mayo Clinic

Angiology | October 12, 2017 | Volume: 69 | Issue: 5 | Pages: 443-448

10.1177/0003319717730636 | PMID 29025284 Get It

Data are limited on whether valvular calcification is associated with aortic wall stiffness. We tested whether aortic valve calcification (AVC) and/or mitral valve calcification (MVC) is inversely associated with aortic distensibility (AD). Cross-sectional study conducted in a subset of the Multi-Ethnic Study of Atherosclerosis (MESA) included 3676 MESA participants aged 44 to 84 years with AD measured with magnetic resonance imaging and with AVC and MVC measured with noncontrast cardiac computed tomography scans. Both AVC and MVC were divided into 3 categories: zero, < median values (low), and ≥ median values (high) for patients with nonzero values. Overall, 88% (n = 3256) and 92% (n = 3365) of participants had zero AVC and MVC, while 6% (n = 211) and 4% (n = 156) had low, and 6% (n = 209) and 4% (n = 155) had high values of AVC and MVC, respectively. The AVC was independently associated with AD after adjusting for age, gender, and ethnicity ( P = .035). No association was noted between AVC groups and AD after adjustment for all covariates or MVC groups and AD in any model.
Prevalence and Outcomes of Left‐Sided Valvular Heart Disease Associated With Chronic Kidney Disease
Samad, Zainab , Sivak, Joseph A. , Phelan, Matthew, Schulte, Phillip J. , Patel, Uptal D. , Velazquez, Eric J.

Mayo Clinic

Journal of the American Heart Association | October 11, 2017 | Volume: 6 | Issue: 10 | Pages: No page available

10.1161/jaha.117.006044 | PMID 29021274 Get It

Background Chronic kidney disease ( CKD ) is an adverse prognostic marker for valve intervention patients; however, the prevalence and related outcomes of valvular heart disease in CKD patients is unknown. Methods and Results Included patients underwent echocardiography (1999–2013), had serum creatinine values within 6 months before index echocardiogram, and had no history of valve surgery. CKD was defined as diagnosis based on the International Classification of Diseases, Ninth Revision or an estimated glomerular filtration rate <60 mL/min per 1.73 m 2 . Qualitative assessment determined left heart stenotic and regurgitant valve lesions. Cox models assessed CKD and aortic stenosis ( AS ) interaction for subsequent mortality; analyses were repeated for mitral regurgitation ( MR ). Among 78 059 patients, 23 727 (30%) had CKD ; of these, 1326 were on hemodialysis. CKD patients were older; female; had a higher prevalence of hypertension, hyperlipidemia, diabetes, history of coronary artery bypass grafting/percutaneous coronary intervention, atrial fibrillation, and heart failure ≥mild AS; and ≥mild MR (all P <0.001). Five‐year survival estimates of mild, moderate, and severe AS for CKD patients were 40%, 34%, and 42%, respectively, and 69%, 54%, and 67% for non‐CKD patients. Five‐year survival estimates of mild, moderate, and severe MR for CKD patients were 51%, 38%, and 37%, respectively, and 75%, 66%, and 65% for non‐CKD patients. Significant interaction occurred among CKD , AS / MR severity, and mortality in adjusted analyses; the CKD hazard ratio increased from 1.8 (non‐ AS patients) to 2.0 (severe AS ) and from 1.7 (non‐ MR patients) to 2.6 (severe MR ). Conclusions Prevalence of at least mild AS and MR is substantially higher and is associated with significantly lower survival among patients with versus without CKD . There is significant interaction among CKD , AS / MR severity, and mortality, with increasingly worse outcomes for CKD patients with increasing AS / MR severity.
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
Lamichhane, Purushottam , Karyampudi, Lavakumar, Shreeder, Barath , Krempski, James , Bahr, Deborah, Daum, Joshua , Kalli, Kimberly R., Goode, Ellen L. , Block, Matthew S. , Cannon, Martin J. , Knutson, Keith L. , Krempski, James W , Knutson, Keith L.

Mayo Clinic

Cancer Research | October 9, 2017 | Volume: 77 | Issue: 23 | Pages: 6667-6678

10.1158/0008-5472.can-17-0740 | PMID 28993412 Get It

Abstract Ligation of programmed cell death-1 (PD-1) in the tumor microenvironment is known to inhibit effective adaptive antitumor immunity. Blockade of PD-1 in humans has resulted in impressive, durable regression responses in select tumor types. However, durable responses have been elusive in ovarian cancer patients. PD-1 was recently shown to be expressed on and thereby impair the functions of tumor-infiltrating murine and human myeloid dendritic cells (TIDC) in ovarian cancer. In the present work, we characterize the regulation of PD-1 expression and the effects of PD-1 blockade on TIDC. Treatment of TIDC and bone marrow–derived dendritic cells (DC) with IL10 led to increased PD-1 expression. Both groups of DCs also responded to PD-1 blockade by increasing production of IL10. Similarly, treatment of ovarian tumor–bearing mice with PD-1 blocking antibody resulted in an increase in IL10 levels in both serum and ascites. While PD-1 blockade or IL10 neutralization as monotherapies were inefficient, combination of these two led to improved survival and delayed tumor growth; this was accompanied by augmented antitumor T- and B-cell responses and decreased infiltration of immunosuppressive MDSC. Taken together, our findings implicate compensatory release of IL10 as one of the adaptive resistance mechanisms that undermine the efficacy of anti–PD-1 (or anti–PD-L1) monotherapies and prompt further studies aimed at identifying such resistance mechanisms. Cancer Res; 77(23); 6667–78. ©2017 AACR.